Roble Belko & Company’s Merck MRK Stock Holding History

Roble Belko & Company’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61K	Buy	478 +2	+0.4%	+$234	0.01%	199
2026 Q1	$57K	Buy	476 +1	+0.2%	+$115	0.01%	200
2025 Q4	$50K	Buy	475 +52	+12%	+$4.88K	0.01%	207
2025 Q3	$35K	Sell	423 -82	-16%	-$6.75K	﹤0.01%	191
2025 Q2	$40K	Sell	505 -72	-12%	-$5.72K	0.01%	190
2025 Q1	$52K	Buy	577 +251	+77%	+$23.4K	0.01%	166
2024 Q4	$32K	Hold	326	–	–	0.01%	191
2024 Q3	$37K	Hold	326	–	–	0.01%	179
2024 Q2	$40K	Hold	326	–	–	0.01%	175
2024 Q1	$43K	Buy	326 +85	+35%	+$10.5K	0.01%	181
2023 Q4	$26K	Buy	241 +49	+26%	+$5.09K	﹤0.01%	187
2023 Q3	$20K	Hold	192	–	–	﹤0.01%	180
2023 Q2	$22K	Sell	192 -2,386	-93%	-$271K	﹤0.01%	184
2023 Q1	$274K	Sell	2,578 -2,386	-48%	-$258K	0.06%	77
2022 Q4	$551K	Hold	4,964	–	–	0.12%	63
2022 Q3	$427K	Hold	4,964	–	–	0.1%	65
2022 Q2	$453K	Hold	4,964	–	–	0.1%	64
2022 Q1	$407K	Sell	4,964 -79	-2%	-$6.23K	0.08%	69
2021 Q4	$386K	Buy	5,043 +79	+2%	+$6.29K	0.07%	67
2021 Q3	$373K	Hold	4,964	–	–	0.08%	61
2021 Q2	$386K	Sell	4,964 -238	-5%	-$17.7K	0.09%	65
2021 Q1	$383K	Hold	5,202	–	–	0.09%	61
2020 Q4	$406K	Hold	5,202	–	–	0.11%	58
2020 Q3	$412K	Sell	5,202 -423	-8%	-$33.1K	0.12%	54
2020 Q2	$415K	Buy	5,625 +423	+8%	+$31.8K	0.12%	52
2020 Q1	$382K	Hold	5,202	–	–	0.12%	57
2019 Q4	$451K	Hold	5,202	–	–	0.12%	57
2019 Q3	$418K	Hold	5,202	–	–	0.12%	54
2019 Q2	$416K	Hold	5,202	–	–	0.13%	52
2019 Q1	$413K	Sell	5,202 -968	-16%	-$72.4K	0.14%	52
2018 Q4	$450K	Buy	6,170 +5,969	+2,970%	+$421K	0.17%	49
2018 Q3	$14K	Hold	201	–	–	0.01%	188
2018 Q2	$12K	Hold	201	–	–	﹤0.01%	208
2018 Q1	$10K	Sell	201 -1,048	-84%	-$56.6K	﹤0.01%	233
2017 Q4	$67K	Buy	1,249 +1,048	+521%	+$58.1K	0.03%	102
2017 Q3	$12K	Sell	201 -108	-35%	-$6.55K	0.01%	173
2017 Q2	$19K	Hold	309	–	–	0.01%	142
2017 Q1	$19K	Hold	309	–	–	0.01%	146
2016 Q4	$17K	Sell	309 -1,894	-86%	-$111K	0.01%	164
2016 Q3	$131K	Buy	2,203 +315	+17%	+$18.4K	0.07%	62
2016 Q2	$104K	Buy	1,888 +1,048	+125%	+$55.8K	0.06%	75
2016 Q1	$42K	Sell	840 -388	-32%	-$19K	0.02%	102
2015 Q4	$62K	Buy	1,228 +388	+46%	+$19.6K	0.04%	88
2015 Q3	$40K	Hold	840	–	–	0.02%	96
2015 Q2	$46K	Hold	840	–	–	0.03%	100
2015 Q1	$46K	Buy	+840	New	+$47.6K	0.03%	97

Other funds holding MRK

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Roble Belko & Company's MRK Position: Q2 2026 in Review

Roble Belko & Company increased its Merck (MRK) stake by 0.42% in Q2 2026, buying an estimated $234 and bringing the position to 478 shares worth $61K. The position accounts for 0.01% of the portfolio, ranked #199.

Roble Belko & Company first reported a position in MRK in Q1 2015 and has held it in 46 quarters since. The position peaked at $551K in Q4 2022. 1,532 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Roble Belko & Company held 478 shares of Merck worth $61K as of Q2 2026.
Roble Belko & Company bought 2 Merck shares in Q2 2026, an estimated $234.
Merck made up 0.01% of Roble Belko & Company's portfolio in Q2 2026, its #199 holding.
Roble Belko & Company first reported a position in Merck in Q1 2015 and has held it in 46 quarters since.
Roble Belko & Company's Merck position peaked at $551K in Q4 2022.
1,532 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Roble Belko & Company's 13F filing for Q2 2026, filed 24 Jul 2026.